Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Shenzhenlubris Pharmaceuticals Co's OCF Margin % or its related term are showing as below:
SZSE:002294'
s OCF Margin % Range Over the Past 10 Years
Min: 24.18 Med: 31.64 Max: 50.18
Current: 23.64
During the past 13 years, the highest OCF Margin % of Shenzhenlubris Pharmaceuticals Co was 50.18%. The lowest was 24.18%. And the median was 31.64%.
SZSE:002294's OCF Margin % is ranked better than 84.94% of 963
companies
in the Drug Manufacturers industry
Industry Median: 9.94
vs SZSE:002294: 23.64
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shenzhenlubris Pharmaceuticals Co OCF Margin % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Shenzhenlubris Pharmaceuticals Co's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shenzhenlubris Pharmaceuticals Co OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shenzhenlubris Pharmaceuticals Co's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Shenzhenlubris Pharmaceuticals Co's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shenzhenlubris Pharmaceuticals Co (SZSE:002294) has a OCF Margin % of 15.08% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Shenzhenlubris Pharmaceuticals Co and its competitors. This is 52% below median its historical median of 31.64. Over the past decade, Shenzhenlubris Pharmaceuticals Co's OCF Margin % has ranged from 24.18 to 50.18. According to the industry distribution chart, Shenzhenlubris Pharmaceuticals Co ranks #145 out of 963 companies in the Drug Manufacturers industry, placing it in the top 15.1%.
Is Shenzhenlubris Pharmaceuticals Co's OCF Margin % too high?
Shenzhenlubris Pharmaceuticals Co's current OCF Margin % of 15.08% is 52% below median its 10-year median of 31.64. Over the past 10 years, this metric has ranged from a low of 24.18 to a high of 50.18. The Drug Manufacturers industry median OCF Margin % is 9.94. Shenzhenlubris Pharmaceuticals Co's value of 15.08% is 51.7% above this industry median. Based on the distribution chart, Shenzhenlubris Pharmaceuticals Co ranks #145 out of 963 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Shenzhenlubris Pharmaceuticals Co has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shenzhenlubris Pharmaceuticals Co's OCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shenzhenlubris Pharmaceuticals Co ranks #145 out of 963 companies for OCF Margin %. This places Shenzhenlubris Pharmaceuticals Co in the top 15% of its industry — outperforming the majority of peers. The industry median OCF Margin % is 9.94. Shenzhenlubris Pharmaceuticals Co's value of 15.08% is 51.7% above this benchmark. Historically, Shenzhenlubris Pharmaceuticals Co's own OCF Margin % has ranged from 24.18 to 50.18 over the past decade. While the company's 10-year median is 31.64 vs. the industry median of 9.94, Shenzhenlubris Pharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.94, based on 963 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shenzhenlubris Pharmaceuticals Co's current OCF Margin % of 15.08% is 51.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Shenzhenlubris Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shenzhenlubris Pharmaceuticals Co's current OCF Margin % is 15.08%, which is 52% below median its own 10-year median of 31.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shenzhenlubris Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Shenzhenlubris Pharmaceuticals Co (SZSE:002294) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥44.01, compared to a current price of ¥33.85 — trading 23.1% below its estimated fair value. The current OCF Margin % is 15.08%, which is 52% below median its 10-year median of 31.64 and 51.7% above the Drug Manufacturers industry median of 9.94. Shenzhenlubris Pharmaceuticals Co's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Shenzhenlubris Pharmaceuticals Co (SZSE:002294), the current OCF Margin % is 15.08% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Overvalued in 2026?
Based on GuruFocus' analysis, Shenzhenlubris Pharmaceuticals Co stock appears to be undervalued.
The current stock price of ¥33.85 is trading 23.1% below its estimated GF Value™ of ¥44.01.
GuruFocus considers Shenzhenlubris Pharmaceuticals Co to be Modestly Undervalued.
Key valuation signals for SZSE:002294:
OCF Margin %: 15.08% (52% below median its 10-year median of 31.64)
GF Value™: ¥44.01 vs. price of ¥33.85 (23.1% below fair value)
Industry Position: 51.7% above the Drug Manufacturers median (#145 of 963)
No single metric tells the full story. See the SZSE:002294 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shenzhen Salubris Pharmaceuticals Co Ltd is a pharmaceutical company dedicated to the research, development, and sale of medical products for cardiovascular diseases, cephalosporins, and bone resorption inhibitors. Its products mainly focus on the areas of cardio-cerebral vascular disease, diabetes, complications, anti-tumor, and orthopedics. Its business lines include high-end chemical drugs, biological drugs, and medical devices. Its businesses are located in China, the United States, Germany, France, and Japan, and other countries and regions.
82GF Score
Get the complete analysis for SZSE:002294
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:002294 has been successfully added to your 
